Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 0.44 |
| ▸ | FNTB | P49356 | 12/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 12/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7677229 | 0.91 | FNTA (0.43) | FNTAFNTBPGGT1BSIGMAR1SLC6A2 | |
| Hydrochloric Acid SCHEMBL7678603 | 0.90 | FNTA (0.42) | FNTAFNTBPGGT1BSIGMAR1 | |
| SCHEMBL7677814 | 0.89 | FNTA (0.42) | FNTAFNTBPGGT1BSIGMAR1SLC6A2 | |
| SCHEMBL8195311 | 0.89 | FNTA (0.41) | FNTAFNTBPGGT1BSIGMAR1KMT2A | |
| SCHEMBL7571079 | 0.87 | FNTA (0.52) | FNTAFNTBPGGT1BSIGMAR1SLC6A2 | |
| SCHEMBL7564884 | 0.87 | FNTA (0.52) | FNTAFNTBPGGT1BSIGMAR1SLC6A2 | |
| SCHEMBL7586274 | 0.87 | FNTA (0.52) | FNTAFNTBPGGT1BSIGMAR1SLC6A2 | |
| Cyclopropane SCHEMBL7680538 | 0.86 | FNTA (0.51) | FNTAFNTBPGGT1BSIGMAR1KMT2A | |
| SCHEMBL7677610 | 0.86 | FNTA (0.41) | FNTAFNTBPGGT1BSIGMAR1KMT2A | |
| SCHEMBL7674299 | 0.85 | GAA (0.41) | FNTAFNTBPGGT1BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| US-6284755-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000034437-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | FNTA, PKD1, FNTB | FNTA 1/4885FNTB 3/4885PGGT1B 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.